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ABSTRACT 
Visceral Leishmaniasis (VL) is a chronic, severe and systemic protozoonosis caused 
by different species of the genus Leishmania sp., which results in death in 90% of 
cases if not treated. Clinical suspicion should be raised when the patient has fever 
and splenomegaly, associated or not with hepatomegaly. This paper presents the 
case report of a patient admitted to Dona Regina Siqueira Campos Maternity 
Hospital, in Palmas, Tocantins, Brazil, with a clinical history of thrombocytopenia 
and splenomegaly, initially diagnosed and treated as a VL, but later diagnosed with 
SC Hemoglobinopathy. During pregnancy, women with HbSC genotype may 
develop complications as severe as those presented by women with HbSS 
genotype. However, the symptoms presented by this patient at the end of 
gestation may also be confused with the VL condition, a diagnosis for which she 
presented two positive laboratory tests.    
Keywords: Visceral Leishmaniasis, Hemoglobinopathy SC, Glucantime®. 
 
RESUMO  
A leishmaniose visceral (LV) é uma protozoonose de evolução crônica, grave e 
sistêmica, causada por diferentes espécies do gênero Leishmania sp., que resulta 
em morte em 90% dos casos se não tratada. A suspeita clínica deve ser levantada 
quando o paciente apresentar febre e esplenomegalia associada ou não à 
hepatomegalia. Apresentamos, neste trabalho, o relato de caso de uma paciente 
que deu entrada no Hospital e Maternidade Dona Regina Siqueira Campos 
(HMDR), em Palmas, Tocantins (TO), com quadro de plaquetopenia e 
esplenomegalia e inicialmente diagnosticada e tratada como um quadro de LV e 
posteriormente diagnosticada com Hemoglobinopatia SC. Durante a gestação, 
mulheres portadoras do genótipo HbSC podem desenvolver complicações tão 
graves quanto as apresentadas por mulheres portadoras do genótipo Hb SS. No 
entanto, os sintomas apresentados pela paciente ao final da gestação podem ser 
confundidos também com o quadro de LV, diagnóstico para o qual apresentou 
dois exames laboratoriais positivos. 
Palavras-chave: Leishmaniose visceral, Hemoglobinopatia SC, Glucantime®. 
 
 
 
 
 
 
Revista de Patologia do Tocantins  2018; 5(3): 37-43.                             DOI: 10.20873/uft.2446-6492.2018v5n3p37 
Resstel et al. 
 
38 
 
Revista de Patologia do Tocantins, Vol. 5 No. 3, Setembro 2018 
 
 INTRODUCTION 
 
Visceral Leishmaniasis (VL), or kalazar, was first 
described in Greece, in 1835, and later in India, in 1882. At 
that time, emphasis was placed on skin darkening, a typical 
aspect of the disease found in India, that usually did not 
manifest in Brazil. This characteristic formed the basis of the 
first denomination of this disease, which was called "black 
fever", "kala-jwar" or "kalazar" by the Indians. In 1903, 
Laveran and Mesnil identified the parasite in material supplied 
by Leishman and Donovan. In Leishman’s honor, the disease 
associated with this parasite was denominated Leishmaniasis, 
which is the most commonly used terminology in Western 
countries.1,2 
VL is a protozoonosis, characterized by a severe and 
systemic chronic evolution, caused by different species of the 
genus Leishmania sp., that results in death in 90% of cases if 
not treated. In the Americas, the disease’s etiological agent is 
L. (L.) chagasi.3,4 Once characterized as an eminently rural 
zoonosis, the disease has undergone changes and has become 
a public health problem as it expanded to urban areas of 
medium and large size, throughout Brazilian territory, 
especially in the 1980s and 1990s.5 VL’s incidence is increasing 
in urban areas, demonstrating the adaptive capacity of the 
vector to environments modified by men, which also suggests 
human action as an important factor in the spread of the 
epidemic.6 
VL is considered a neglected disease by the World 
Health Organization (WHO). It caused more deaths in Brazil 
between 2000 and 2011 than dengue and malaria, occupying 
the third place in terms of mortality among neglected 
diseases, that is, those that affect mostly people living in 
poverty, without adequate sanitation, and in close contact 
with infectious vectors.7,8 
This zoonosis is present in all continents, in more 
than 60 countries. However, more than 90% of registered 
cases are concentrated in only 6 of them: India, Bangladesh, 
Sudan, South Sudan, Brazil and Ethiopia.9 WHO estimates that 
500,000 new cases and 59,000 deaths occur worldwide every 
year.10 In Brazil, VL has autochthonous cases in 25% of 
municipalities, in 21 of its 26 states.8 According to the Ministry 
of Health, in 2015, the Tocantins (TO) state had the highest 
incidence among Brazilian states, with 12.2 cases / 100,000 
inhabitants.11 
In Tocantins, urbanization of the vector and spread 
of the disease has taken place due to ecological changes 
caused by the entry of men into wild sites, such as: the 
construction of the state’s capital; interest in activities related 
to the penetration of forests; common habits among the 
population, like raising animals in backyards or urban streets; 
the intense migratory flow; and the lack of basic sanitation 
structure.12 
In urban areas, the dog (Canis familiaris) is the main 
reservoir of VL, while in the wild, foxes (Dusicyon vetulus and 
Cerdocyon thous) and marsupials (Didelphis albiventris) are 
the main source of infection. The disease is transmitted 
through blood-sucking insects infected with Leishmania (L.) 
chagasi. In Brazil, two species are related to the transmission: 
the main one, Lutzomyia longipalpis; and Lutzomyia cruzi, 
specificly in areas of Mato Grosso and Mato Grosso do Sul 
states. The possibility of a third species (Lutzomyia migonei) 
being involved in the transmission is still studied due to its 
high density in sites with absence of L. longipalpis and/or L. 
cruzi and autochthonous cases of the disease.13 
Clinical suspicion should be raised when a patient 
presents with fever and splenomegaly, associated or not with 
hepatomegaly.14 In Brazil and worldwide, there are few 
reports of VL in pregnant women and, between those 
available, the cases originate from regions known to be 
endemic for the disease.15 However, with the spread of the 
disease between urban and peri-urban areas in Brazil, where 
adults were generally not exposed to Leishmania sp., cases of 
pregnant women with VL have already been reported.16 
This paper reports the case of a patient who was 
admitted to the Hospital e Maternidade Dona Regina Siqueira 
Campos (HMDR), in Palmas / TO, with a clinical history of 
thrombocytopenia and splenomegaly, initially diagnosed and 
treated as VL. 
 
CASE REPORT  
 
S. N. S., female, 36 years old, she was gravida 3 para 
2 having had two previous cesarean deliveries and none 
miscarriage, brown, in a stable union, coming from Taguatinga 
/ TO. She was referred to HMDR, in Palmas / TO, with 38 
weeks of gestation (calculated by ultrasonography (USG) of 15 
weeks and 4 days) for obstetric evaluation due to 
thrombocytopenia. She had received adequate prenatal care. 
The patient reported that in a previous pregnancy, she 
presented the same clinical scenario at the end of gestation. 
She reports that, at the time, she gave birth to a stillborn fetus 
via cesarean delivery. She denied comorbidities or continuous 
use of medications, but claimed a family history of sickle cell 
anemia (sibling). 
At hospital admission, the patient complained of 
asthenia and reported having long-standing 
thrombocytopenia and anemia, with unknown cause. At 
physical examination, she was pale (+ / 4 +), icteric (+ / 4 +), 
hydrated, eupneic, and hemodynamically stable. A palpable 
spleen, 6 cm below the left costal border, was detected. USG 
showed an increased spleen, measuring approximately 19 x 14 
x 7 cm. Doppler flow of the umbilical artery within normality. 
In laboratory tests from admission, hemoglobin 
(Hb): 10.6 g / dl; hematocrit (Ht): 30.9%; leukocytes: 9,980 / 
mm³; platelets: 86,000 / mm³; clotting time (CT): 5 minutes; 
bleeding time (BT): 1.30 minutes; prothrombin time (PT): 
12.20 seconds; INR: 0.90; active partial thromboplastin time 
(APTT): 30 seconds; urea: 21.0 mg / dl; creatinine: 0.7 mg / dl; 
alanine aminotransferase (ALT): 14U / L; aspartate 
aminotransferase (AST): 26 U / L; urinalysis: no alterations. 
Eight hours after admission to the maternity ward, 
the obstetric team’s decision was to perform a cesarean 
delivery. There were no intercurrences during the surgery, and 
a term newborn, adequate to gestational age, was delivered in 
good vitality. 
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On the first 
postoperative day 
(POD), new 
complementary 
exams were 
requested for 
etiological 
investigation. Vitamin 
B12: 127 pg / ml; 
serum ferritin: 376.9 
ng / ml; total 
proteins: 6.00 g / dl; 
albumin: 3.10 g / dl; 
globulins: 2.90 g / dl; 
lactic dehydrogenase 
(LDH): 451.0 IU / L; 
total bilirubin: 0.60 
mg / dl; direct 
bilirubin: 0.27 mg / 
dL; indirect bilirubin: 
0.33 mg / dl. alkaline 
phosphatase 110 U / L; gamma glutamyl transferase (GGT): 
15.0 U / L. 
Five days after delivery, the presence of phlogistic 
signs and bulging in the incision site were noted. Antibiotic 
therapy with Cefalotine 1g, 6 / 6h, was initiated. An USG of the 
region showed laminar net collections along the surgical scar, 
related to seroma. The exit of purulent secretion through the 
operative wound (OW) was observed, and manual drainage 
was performed. 
On the 7th day of hospitalization, a rapid test for 
Leishmania sp. (Kala-azar Detect®) showed a positive result. 
Indirect Immunofluorescence Serology for Human Visceral 
Leishmaniasis (IgG), collected in the 1st POD, was reagent, 
title 1:80. With the results of rapid test and serology, 
treatment for VL with Meglumine Antimoniate (Glucantime®), 
14.8 ml intravenous (EV), once daily (20 mg Sb+ 5 / kg / day) 
was started. She completed 8 days of Cefalotine, at the 12th 
POD, with improvement of phlogistic signs in the OW, but 
persistent seroma output. Dressing was performed three 
times a day, with vigorous expression of the wound and 
progressive decrease of secretion. 
She evolved with no further complaints and 
important improvement of the overall scenario. Breastfeeding 
was discontinued due to use of Glucantime®, in accordance to 
pediatrics’ and infectlogist’s recommendations.  
At the beginning of treatment for VL, an evaluation 
from the infectious disease service was requested, which 
occurred on the fifth day of treatment. Since the patient did 
not present clinical and laboratory findings compatible with VL 
(no fever, no AST / ALT alterations, and no leucopenia), it was 
decided to carry out a direct bone marrow search for 
diagnostic confirmation. On the sixth day of treatment, after 
reviewing the medical record and the direct search for 
Leishmania sp. in the bone marrow, the infectious team 
considered that the patient did not present a clinical picture 
compatible with VL. Suspension of Glucantime® and release of 
breastfeeding were recommended.  
However, due to observation of significant clinical 
and  laboratory  improvement,  with  an  expressive increase in  
Graphic 1: Platelet count during hospitalization 
 
platelet count (Graphic 1) and considering that the myelogram 
was performed in an inopportune time, the HMDR medical 
team insisted on the diagnosis of VL and opted for treatment 
until the tenth day. On the tenth day of treatment for VL, the 
patient presented general malaise and dyspnea on minimal 
exertion. Laboratory tests showed severe anemia, with Hb 4.7 
g / dL, Ht: 14.6%. Four red blood cells concentrates were 
transfused and Glucantime® treatment was suspended. 
Three days after Glucantime® withdrawal, on the 
22nd caesarean section POD, she was admitted to the 
emergency room of the Hospital Geral Público de Palmas 
(HGPP), with severe fatigue, malaise, arthralgia and fever 
sensation. At physical examination she was lucid, oriented, 
Glasgow Coma Scale (GCS 15), dehydrated 3 + / 4 +, 
hypoxemic 2 + / 4 +, anicteric, afebrile. She presented dyspnea 
at minimal efforts, in use of O2 under mask at 5 liters / min. 
Blood Pressure: 156x82 mmHg. Heart Rate: 56-77 bpm. 
Abdomen: globose, distended, painful at palpation on the left 
hypochondrium, with splenomegaly of approximately 7cm 
below the left costal border, hepatomegaly 2cm below the 
right costal border. Cardiovascular and respiratory systems 
showed no alterations. 
Electrocardiogram revealed sinus bradycardia, with 
a heart rate of 40 bpm. Evaluation from cardiology and 
hematology services, as well as laboratory tests and chest X-
ray were requested. Sepsis protocol was initiated (Ceftriaxone 
1g EV 12 / 12h and Clindamycin 600mg EV 8 / 8h) and a spot in 
the Intensive Care Unit (ICU) was requested. 
The patient presented a normal echocardiogram, 
with an ejection fraction of 73%. Cardiotoxicity due to use of 
Glucantime® was suspected, restriction of cardiotoxic 
medications was recommended. In the 23rd postoperative 
day, she was admitted to the adult ICU, where she received 
transfusion of two phenotyped red blood cell concentrates, 
two fresh frozen plasma concentrates and two platelet 
concentrates due Ht: 18.4%, Hb 5.2 g / dL; 93.000 / mm³ 
platelets; PT of 12 seconds; RNI 0.97 and APTT  of 25 seconds. 
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She was discharged from the ICU to the clinic ward after 5 
days, where she finished an antibiotic regimen (10 days) and 
maintained hepatosplenomegaly without abdominal pain. 
She was evaluated by the Hematology team and 
received the diagnosis of Hemoglobinopathy SC. Hemoglobin 
electrophoresis showed Hb A2/C/E 33.2%; Hb S/D/G 34.2%; 
HbF 0.3% and HbA 32.2%. Peripheral blood smear was also 
evaluated (Picture 1). 
  
Picture 1: Peripheral blood smear showing target red blood 
cells. Microscopy performed at the hematology department of 
the Hospital Geral Público de Palmas (HGPP). 
 
The patient evolved with clinical improvement and 
no complaints, maintaining hepatosplenomegaly and 
bicytopenia. She was discharged with prescription of folic acid 
and acetaminophen in case of pain. She was referred to the 
HGPP hematology outpatient clinic. 
 
DISCUSSION 
 
Differential diagnosis among the various causes of 
thrombocytopenia is a challenge in clinical practice. Splenic 
aspirate is considered the most sensitive VL’s diagnostic 
method (96.4%), followed by bone marrow aspirate (70.2%). 
Serological tests are indirect methods of parasite detection. 
They precede parasitological evaluation because of their 
practicality. However, indirect immunofluorescence (IIF) may 
cross-react with antigens from other organisms.17 
 
WRONG DIAGNOSIS OF VL? 
 
VL is a very serious systemic infection that affects 
internal organs, such as the spleen, liver, bone marrow and 
lymph nodes. Clinical features include prolonged fever, 
fatigue, weight and appetite loss, and hepatosplenomegaly.18 
In both clinical and control programs, diagnosis of VL remains 
a challenge. The parasitological diagnosis requires microscopic 
demonstration of Leishmania sp. amastigotes in tissue biopsy 
specimens. The most sensitive tissue biopsy specimen for 
detecting amastigotes is the splenic aspirate, but this 
procedure carries the risk of fatal hemorrhage. Biopsy samples 
from other tissues, such as bone marrow or lymph nodes, are 
associated with fewer risks, but their sensitivities are 
substantially lower. Alternative diagnostic procedures are 
serological diagnosis19-22 and nucleic acid amplification, such as 
PCR techniques.23-24 Although PCR seems reasonably sensitive 
and specific for detection of Leishmania sp. infections23, not 
only is this technology difficult to apply, it has not yet been 
standardized for practical conditions. In addition, in areas of 
endemicity, PCR may be very sensitive in clinical scenarios, as 
it detects many asymptomatic infections.25 Several serological 
tests, such as immunofluorescence and enzyme-linked 
immunosorbent assay (ELISA), have been used for many years 
in laboratories, but it was not until the development of the 
direct agglutination test in the 1980s that the serological 
diagnosis became feasible in practical settings.26 , 27 
In this report, the rapid test used for detection of 
Leishmania sp. was the Kala-azar Detect® test, whose result 
was positive. A study conducted by Peruhype-Magalhães and 
colleagues28, compared the performance of two rapid tests 
(Kala-Azar Detect® and IT-LEISH®) and a serological test (IFI-
LH®) for the diagnosis of VL. Sensitivity values were similar for 
both rapid tests, but the specificity and positive predictive 
value of IT-LEISH® were higher than the corresponding values 
for IFI-LH®. Both rapid tests showed satisfactory performance 
and can then be used in primary health care settings; 
however, IT-LEISH® allows the use of whole blood samples, 
making it more suitable for the diagnosis of the disease. 
In our patient, a second test, the IIF serology for 
Human Visceral Leishmaniasis (IgG), showed a positive result 
of 1:80. It was collected in the 1st POD, when treatment with 
Meglumine Antimoniate (Glucantime®) was started. 
A study conducted by Silveira and colleagues29 
included VL patients whose diagnosis were confirmed using 
clinical-epidemiological, serological or parasitological criteria 
and who were admitted and prescribed for treatment with 
Glucantime®. Clinical and epidemiological diagnosis were 
considered for patients who had fever and 
hepatosplenomegaly and were native from regions considered 
endemic. In this study, all 89 patients underwent a 
parasitological diagnosis of bone marrow aspirate. Of this 
total, 68 (76.40%) were positive and 21 (23.60%) were 
negative. Among those who were negative in bone marrow 
aspirate, three were confirmed by the IIF immune method, 
while the others were treated based on clinical and 
epidemiological criteria. 
Another study carried out in Madrid, Spain, 
confirmed the diagnosis predominantly by bone marrow 
aspirate in 77% of the patients in included in the research. 
According to these results, the diagnosis of VL, based on the 
finding of the parasite in the aspirate of bone marrow aspirate 
continues to be the diagnostic test carried out in the area. But 
it is important to understand that even a direct parasitological 
test may present false negatives, as was the case of our 
patient30, according to the consideration given by the 
infectious disease service (that the patient did not have a 
diagnosis compatible with VL). 
In a study whose objective was to elucidate the 
clinical, epidemiological and biological profile of VL in children 
hospitalized at the Infantile Hospital of Rabat, while proving 
the contribution of serology in the diagnosis of this disease, 
showed results that confirm that the triad - splenomegaly, 
pallor and fever - is a good diagnostic element, while the 
detection of the parasite in the bone marrow continues to be 
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the best way to establish the positive diagnosis of this 
disease.31 
Tato and colleagues30 retrospectively reviewed the 
medical records of children diagnosed with VL between 
January 1994 and December 2007, in a tertiary hospital in 
southern Madrid. The diagnosis of VL was based on the 
visualization of Leishmania sp. in bone marrow aspirate or 
culture, or positive PCR analysis of bone marrow aspirate. 
Aspiration was performed in all patients. Microscopic 
examination of the aspirate detected the presence of 
intracellular amastigotes in 73% of cases. The presence of 
parasite DNA was detected in all cases. The IIF titers were 
greater than 1:40 at the time of diagnosis in 63% of cases. The 
determination of the parasite antigen in the urine was positive 
in 4 of 6 patients (67%). 3 patients were treated with N-methyl 
Glucamine Antimoniate and 8 patients (73%) with Liposomal 
Amphotericin B. An early clinical response was observed in all 
patients. These results show how the polymerase chain 
reaction technique in the aspirate of bone marrow presented 
greater sensitivity than traditional techniques. However, it is 
important to note that noninvasive techniques may also be 
useful in patients with compatible clinical symptoms. 
In our case, the HMDR medical team chose to 
maintain VL treatment up until the tenth day because of the 
significant clinical improvement presented by the patient and 
given that the myelogram was considered to have been 
performed in an inopportune time. We understand that the 
conduct in this case has been scientifically supported, since 
the direct research of the parasite in bone marrow aspirate 
can be negative, while the polymerase chain reaction of this 
material would be the ideal diagnostic technique, since it 
presents greater sensitivity. 
 
GLUCANTIME® AND BREASTFEEDING  
 
The use of Glucantime® for the treatment of VL in 
women who are breastfeeding is controversial. In the drug’s 
leaflet, it is noted that due to lack of studies, the use of this 
medication is not recommended during pregnancy. But the 
physician must weigh the benefit of both treatment and 
breastfeeding.32 
However, in the Visceral Leishmaniasis Surveillance 
and Control Manual, it is stated that there is no 
contraindication of Glucantime® during breastfeeding.33 In the 
reported case, the medical team chose to discontinue 
breastfeeding during treatment with Glucantime®, backed by 
the drug leaflet. 
GLUCANTIME® CARDIOTOXICITY 
 
Glucantime® is considered relatively safe and 
effective in the treatment of VL. However, it is related to some 
adverse effects, such as arthralgia, myalgia, anorexia, nausea, 
vomiting, abdominal pain, headache, dizziness, palpitations, 
hepatic, renal and pancreatic dysfunctions, as well as 
abnormalities in the electrocardiogram at rest.35 
The cardiotoxicity of Glucantime® is mainly due to 
alterations in the electrocardiogram, such as changes in the T 
wave, a long QT interval, and bradycardia.36 In this case, the 
patient presented symptomatic bradycardia associated with 
the use of Glucantime®. 
Cardiotoxicity is directly proportional to the dose 
and the time of treatment.37 Although electrocardiographic 
changes are not frequent and, when they occur, tend to be 
reversible, there is a significant potential for morbimortality, 
as evidenced by reports of sudden death associated with the 
use of this drug.35 Therefore, patients using this medication 
require rigorous electrocardiographic monitoring.36 
 
HEMOGLOBINOPATHY SC  
 
Hemoglobin SC disease (HbSC) is the most frequent 
hemoglobinopathy after sickle cell anemia. It occurs when the 
individual inherits a βC gene for hemoglobin C from one 
parent and the βS gene for hemoglobin S from the other. 
HbSC red blood cells contain equal levels of HbS and HbC and 
the blood smear of these individuals contains mainly target 
cells with few sickle cells.38 
  Medical advances in the last decades, with the 
introduction of new therapies, have been responsible for 
increasing the life expectancy of these patients, but 
management of this disease during pregnancy and 
puerperium continues to be a great challenge.39 
Non-pregnant women with SC hemoglobinopathy, a 
less severe clinical form, may be asymptomatic or 
oligosymptomatic; however, during pregnancy, they may 
develop complications as severe as those presented by 
women with the HbSS genotype, which is explained by 
physiological changes during this period.40 
Studies have already shown an increased  mortality 
rate among these pregnant women, especially in the third 
trimester, as well as among women in puerperium.39 It is 
known that there is a 10 to 15% increase in plasma volume 
between the sixth and twelfth week of gestation and between 
30 and 34 weeks, when a faster and more significant increase 
occurs, which induces a modest decrease in hemoglobin levels 
during gestation.41 Other physiological changes capable of 
justifying the increase of theses patients' morbidity and 
mortality in the third trimester and in the puerperium are: 
hypercoagulability, increased susceptibility to infections and 
hormonal variations.40 
In our case, the patient was diagnosed with SC 
hemoglobinopathy through hemoglobin electrophoresis 
associated with peripheral blood smear evaluation, which 
showed the presence of target red blood cells. Compared to 
patients with SS hemoglobinopathy, patients with SC 
hemoglobinopathy present lower mortality and morbidity, 
with occurrence of less severe complications, as well as better 
obstetric and perinatal outcomes.39 However, complications 
including painful crises, preterm birth, pre-eclampsia and 
postpartum hemorrhage have been well documented in the 
literature for both HbSS and HbSC. Although these 
complications occur less frequently in the HbSC disease, there 
were no statistically significant differences between the two 
genotypes.38 
       Regarding pulmonary complications, a study 
carried out in Belo Horizonte, Minas Gerais (MG) showed that 
the main cause of maternal death was acute chest syndrome 
and that the risks among the carriers of the HbSC and HbSS 
subtypes were very similar. Thromboembolism and pulmonary 
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infarction are also generally fatal complications occurring 
mainly during the third trimester and puerperal period.40 
Although prophylactic transfusions are commonly 
used in pregnant patients with hemoglobinopathies, there is 
still no evidence that this practice is superior to those 
performed on demand.39 Careful hematological and obstetric 
monitoring is therefore essential to ensure adequate 
management of pregnant and puerperal women with SC 
hemoglobinopathy, as well as early recognition of 
hemoglobinopathy complications and need of 
hemotransfusion.40 
CONCLUSION 
 
During pregnancy, women with the HbSC genotype 
may develop complications as severe as those presented by 
women with the HbSS genotype. However, the symptoms 
presented by the patient at the end of gestation may also be 
confused with the VL condition, a diagnosis for which she 
presented two positive laboratory tests. In Brazil and in the 
world, there are few reports of VL in pregnant women, and of 
those available, the cases‘origin is from regions known to be 
endemic to the disease, such as Tocantins. The use of 
Glucantime® for treatment of VL in women who are 
breastfeeding is controversial. Therefore, we believe that the 
conduct of maintaining Glucantime® despite the bone marrow 
aspirate negative result has scientific support. The direct 
search of the parasite in the bone marrow can be negative, 
while the polymerase chain reaction of this material would be 
the ideal diagnostic technique, since it presents greater 
sensitivity. 
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